<DOC>
	<DOCNO>NCT02615691</DOCNO>
	<brief_summary>The purpose study investigate safety , immunogenicity hemostatic efficacy PEGylated recombinant FVIII ( BAX 855 ) previously untreated ( PUPs ) minimally treat patient ( MTPs ) ≤ 3 EDs ADVATE BAX 855 &lt; 6 year age severe hemophilia A ( baseline FVIII level &lt; 1 % )</brief_summary>
	<brief_title>BAX 855 Previously Untreated Patient ( PUP )</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Participant &lt; 6 year old time screen 2 . Participant previously untreated minimally treat 3 . Participant severe hemophilia A ( Factor VIII ( FVIII ) &lt; 1 % ) 4 . Participant immune competent CD4+ count &gt; 200 cells/mm^3 5 . Parent legally authorize representative willing able comply requirement protocol Additional inclusion criterion Part B ( Immune tolerance induction ( ITI ) ) 1 . Parent legal representative has/have voluntarily provide sign informed consent ITI portion 2 . Participant confirm inhibitor titer ( ≥ 0.6 Bethesda unit ( BU ) ) require ITI therapy 1 . Participant detectable FVIII inhibitory antibody ( ≥ 0.6 BU ) 2 . Participant history FVIII inhibitory antibody ( ≥ 0.6 ) time prior screen 3 . Participant diagnose inherit acquire hemostatic defect hemophilia A 4 . Participant previously treat fresh frozen plasma ( FFP ) , cryoprecipitate , type FVIII concentrate ADVATE BAX 855 administer ADVATE BAX 855 &gt; 3 EDs time prior screen 5 . Participant receive kind bloodtransfusion pack red blood cell ( PRBC ) , platelets plasma time prior screen 6 . The participant 's weight &lt; 5 kg 7 . Participant 's platelet count &lt; 100,000/mL 8 . Participant know hypersensitivity towards mouse hamster protein , PEG Tween 80 9 . Participant severe chronic hepatic dysfunction medical history time screen 10 . Participant severe renal impairment 11 . Participant current recent ( &lt; 30 day ) use PEGylated drug prior study participation schedule use drug study participation 12 . Participant schedule receive course study systemic immunomodulating drug antiretroviral chemotherapy 13 . Participant participate another clinical study involve investigational product ( IP ) investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study 14 . Parent legally authorize representative medical , psychiatric , cognitive illness recreational drug/alcohol use , opinion investigator , would affect subject safety compliance 15 . Parent , legally authorize representative participant member team conduct study dependent relationship one study team member Additional exclusion criterion Part B ( ITI ) 1 . Spontaneous disappearance inhibitor prior ITI 2 . FVIII inhibitor titer ≥ 0.6 BU confirm second new blood sample determine central laboratory 3 . Inability unwillingness comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>